Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02622178 · ClinicalTrials.gov registry record · NA
How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?
A NA study, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 136
- Enrollment target
NCT02622178 is a NA study that has completed, run by Wills Eye. The registered enrollment target is 136 participants.
The verdict
NCT02622178, a NA study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
Study Summary
Evaluate sensitivity and specificity of NOVA-DN visually evoked potentials (VEP) protocol and new software method (Corda) for glaucoma detection using optical coherence tomography (OCT) images to differentiate between normal subjects and glaucoma suspects.
Interventions
- DIAGNOSTIC_TEST Optical Coherence Tomography
- DIAGNOSTIC_TEST Visual evoked potential
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02622178
The ClinicalTrials.gov registry entry for NCT02622178 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Optical Coherence Tomography is the first listed.
NCT02622178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02622178 about?
NCT02622178 is a clinical study titled "How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?". Evaluate sensitivity and specificity of NOVA-DN visually evoked potentials (VEP) protocol and new software method (Corda) for glaucoma detection using optical coherence tomography (OCT) images to differentiate between normal subjects and glaucoma suspects.
What is the current status of trial NCT02622178?
This trial is currently completed. It is a NA study. The enrollment target is 136 participants. The study started on 2011-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT02622178?
The interventions under investigation include: Optical Coherence Tomography (DIAGNOSTIC_TEST), Visual evoked potential (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02622178?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.